Trial Profile
Pilot-study: Predicton of response on Lu177-radioligand therapy in metastatic prostate carcinoma by early serial PSA-value examination - PCA-PSA-EPBR
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2019
Price :
$35
*
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- Acronyms PCA-PSA-EPBR
- 08 Oct 2019 Status changed from recruiting to completed.
- 04 Jan 2018 New trial record